We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    bb4 | South Korea
Previous Study | Return to List | Next Study

Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05232175
Recruitment Status : Completed
First Posted : February 9, 2022
Last Update Posted : December 13, 2022
Information provided by (Responsible Party):
Alteogen, Inc.

Brief Summary:
A Phase I Study to Evaluate the Tolerance, Safety and Pharmacokinetics of ALT-BB4 in Healthy Volunteers

Condition or disease Intervention/treatment Phase
Health, Subjective Drug: ALT-BB4 Drug: 0.9%NaCl Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 290 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I Study to Evaluate the Tolerance, Safety and Pharmacokinetics of ALT-BB4 in Healthy Volunteer
Actual Study Start Date : January 18, 2022
Actual Primary Completion Date : August 24, 2022
Actual Study Completion Date : August 24, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Safety

Arm Intervention/treatment
Experimental: Part I (Allergy assessment) - ALT-BB4 Drug: ALT-BB4
Recombinant Hyaluronidase

Placebo Comparator: Part I (Allergy assessment) - 0.9%NaCl Drug: 0.9%NaCl
Normal Saline

Experimental: Part II-A (PK assessment) Drug: ALT-BB4
Recombinant Hyaluronidase

Experimental: Part II-B (Safety assessment) - ALT-BB4 Drug: ALT-BB4
Recombinant Hyaluronidase

Placebo Comparator: Part II-B (Safety assessment) - 0.9% NaCl Drug: 0.9%NaCl
Normal Saline

Primary Outcome Measures :
  1. Incidence rate of drug allergy following ID injection of the IP [ Time Frame: 2 days ]
    Subject developing either immediate or delayed allergic reaction are considered to have drug allergy.

  2. Safety and tolerability assessment following SC injection of the IP [ Time Frame: 4 weeks ]
    Incident rate of adverse events, including systemic and administration site-related adverse events.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:


  1. Healthy volunteers aged ≥19 years at the time of Screening (Visit 1)
  2. Female subjects or male subjects' female partner must be menopausal or should have received a sterilization procedure or have agreed to use contraceptive methods during the study period, as defined below:

    • Post-menopausal female subjects or male subjects' female partners (non-drug induced amenorrhea for at least 12 months or confirmed diagnosis with menopause)
    • Female subjects or male subjects' female partners who have received a sterilization procedure (removal of ovary and/or uterus)
    • Subjects who have agreed to practice total abstinence during the study period [For female subjects, periodic abstinence (e.g., ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.]
    • When female subjects or male subjects' female partners are women of childbearing potential (WOCBP) who have not received a sterilization procedure, they must agree to use of following contraceptive methods:
    • Hormones (implantable, patch, and oral)
    • Intrauterine device (IUD)
    • Double barrier methods (concomitant use of two of following contraceptive methods: male condom, female condom, cervical cap, diaphragm, sponge, spermicide) (However, concomitant use of male condom and female condom is excluded from double barrier methods.)
  3. WOCBP or females who have the last menstrual period within 12 months must have a negative serum or urine pregnancy test at Screening (Visit 1).
  4. Subjects who have voluntarily decided to take part in the study and able to comply with the study protocol
  5. Subjects who have no tattoo, acne, dermatitis, pigmentation or lesion on the administration site and who have no damage in the skin, so that they can receive the IP and allergy test
  6. Subjects determined eligible for the study through Screening tests (vital signs, physical examination, medical history and surgery history, ECG, and laboratory tests)

    Part II-A

  7. Subjects with BMI no less than 18.5 kg/m2, no greater than 24.9 kg/m2

Exclusion Criteria:


  1. Subjects who have received or treated with following medications within the specified timeframe prior to Screening (Visit 1) or who are expected to receive them during the study period:

    • Within 1 month: Hyaluronidase, Chemotherapeutic agent, non-steroidal anti-inflammatory drugs (NSAIDs; e.g.: Aspirin, Aceclofenac, etc.), penicillins antibiotics (e.g.: Amoxicillin, Ampicillin, etc.), cephalosporins antibiotics (e.g.: Cefaclor, Cefadroxil, Cefixime, etc.), sulfonamides antibiotics (e.g.: Sulfadiazine, Sulfamethoxazole, etc.), quinolones antibiotics (e.g.: Ciprofloxacin, Levofloxacin, etc.), Glucocorticosteroid, Immunosuppressive agent
    • Within 14 days: Antihistamine (e.g.: Chlorpheniramine, Hydroxyzine, Ketotifen, etc.)
  2. Subjects who have prior history of clinically significant liver, kidney, nervous system, immune system, respiratory system, endocrine system, hematology/neoplasm, cardiovascular system, mental (mood disorder, obsessive-compulsive disorder), gastrointestinal disorders or surgical history
  3. Subjects with acute fever > 37.5℃ within 7 days from the expected IP administration or showing symptoms suspecting acute diseases within 14 days from the expected IP administration
  4. Subjects who do not have normal blood pressure*

    *Range of normal blood pressure is defined as systolic and diastolic blood <120/80 mmHg in accordance with 2018 Korean Society of Hypertension Guidelines for the Management of Hypertension24) (however, Pre-hypertension (≥ 130/80) is excluded that may occur in normotension).

  5. Subjects who persistently drink more than the weekly recommended alcohol units* 14 g of alcohol content per unit is applied, which corresponds to 1 can (small bottle) of beer (5%), 350 mL of draft beer (5%), 1 cup (300 mL) of makgeoli, 1 glass (150 mL) of wine (12%), 1/4 bottle (90 mL) of soju (20%), and 1 shot (45 mL) of liquor (40%). Moderate amount of alcohol by age and gender is provided below:23) Age Recommended unit per week Adults (≥ 19 and < 65 years) Male: 8 units/week Female: 4 units/week Elderly (≥ 65 years) Male: 4 units/week Female: 2 units/week
  6. Subjects of usual smoker (exceeding 10 cigarettes per day)
  7. Subjects who have a past history of autoimmune diseases (e.g.: rheumatoid arthritis, etc.) or active immune diseases that may affect the immune system [e.g.: flu, cancer, Human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV) etc.], diabetes mellitus, heart diseases, asthma, sinusitis, chronic urticaria, dermographism, or any skin conditions that may affect post-IP administration assessments (e.g.: Dermatitis, dermatomycosis and other skin diseases or tattoo)
  8. Subjects with known allergic reactions or hypersensitivity to bee sting or other common allergens or known contraindications to hyaluronidase, thimerosal (disinfectants) and EDTA
  9. Subjects with hypersensitivity to the IP or its ingredients or a history of anaphylaxis
  10. Past history of drug abuse
  11. Subjects who have participated in other clinical trials within 6 months prior to the expected IP administration
  12. Others determined ineligible for the study participation in the opinion of investigator

    Part II-A

  13. Subjects who have been treated with a drug-metabolizing enzyme inducers and inhibitors*25), 26) within 30 days prior to the IP administration

    * Example: Phenytoin, Carbamazepine, Barbiturates, Rifampicin, Griseofulvin, Cimetidine, Disulfiram, Erythromycin, Ketoconazole, Fluconazole, Itraconazole, Valproic acid, Isoniazid, Ciprofloxacin, Omeprazole, Clarithromycin, Quinidine, Sulfonamides, etc.

  14. Subjects who have significant bleeding or blood loss within 60 days prior to Screening (Visit 1)
  15. Subjects who have donated whole blood within 60 days or donated blood by apheresis within 14 days or received transfusion within 14 days prior to Screening (Visit 1)
  16. Subjects who have consumed grapefruit juice28) within 7 days prior to Screening (Visit 1)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05232175

Layout table for location information
Korea, Republic of
Research Site
Seoul, Korea, Republic of
Sponsors and Collaborators
Alteogen, Inc.
Layout table for additonal information
Responsible Party: Alteogen, Inc.
ClinicalTrials.gov Identifier: NCT05232175    
Other Study ID Numbers: ALT-BB4-01
First Posted: February 9, 2022    Key Record Dates
Last Update Posted: December 13, 2022
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No